1273 studies found for:    Open Studies | "Leukemia"
Show Display Options
Rank Status Study
21 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913
22 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
23 Recruiting Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: selinexor;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Not yet recruiting S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
25 Recruiting Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
Conditions: Leukemia;   Myelodysplasia;   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia
Interventions: Procedure: Umbilical Cord Blood Transfusion;   Drug: Fludarabine;   Drug: Busulfan;   Drug: Melphalan
26 Recruiting Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Acute Undifferentiated Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: lestaurtinib;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: prednisone;   Drug: methylprednisolone;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Drug: hydrocortisone sodium succinate;   Other: laboratory biomarker analysis;   Other: pharmacological study
27 Recruiting Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia
Interventions: Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Procedure: umbilical cord blood transplantation;   Procedure: double-unit umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
28 Unknown  Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Conditions: Myelodysplastic Syndrome;   Myelofibrosis;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Luitpold Azacitidine;   Drug: Vidaza®
29 Recruiting Ruxolitinib for Adult T-Cell Leukemia
Conditions: T Cell Leukemia, Adult;   Leukemia, Adult T-Cell;   T Cell Leukemia, HTLV I Associated
Intervention: Drug: Ruxolitinib
30 Not yet recruiting Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Dietary Supplement: curcumin;   Dietary Supplement: cholecalciferol;   Other: laboratory biomarker analysis;   Other: pharmacological study
31 Recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
32 Not yet recruiting Red Cell Transfusion Goals in Patients With Acute Leukemias
Conditions: Acute Lymphoblastic Leukemia;   Acute Lymphocytic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Acute Promyelocytic Leukemia (APL)
Interventions: Procedure: RBC transfusion with transfusion threshold of 7g/dL Hb;   Procedure: RBC transfusion with transfusion threshold of 8g/dL Hb
33 Recruiting Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia
Interventions: Biological: human myeloid progenitor cells;   Drug: G-CSF
34 Recruiting Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Conditions: Relapsed Acute Lymphoblastic Leukemia;   Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
35 Recruiting Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Lymphoblastic Lymphoma;   Diffuse Large B-cell Lymphoma;   Burkitt Lymphoma/Leukemia
Interventions: Drug: Clofarabine;   Drug: Mitoxantrone
36 Recruiting A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
37 Recruiting Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
38 Recruiting Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: mitoxantrone hydrochloride;   Drug: cytarabine;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
39 Recruiting Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
Conditions: Acute Undifferentiated Leukemia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Mast Cell Leukemia;   Myeloid/NK-cell Acute Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Intervention: Procedure: bioelectric impedance analysis
40 Recruiting Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: lenalidomide;   Drug: cytarabine;   Drug: idarubicin;   Other: pharmacological study;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years